Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2022

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

TCT 52: Structural and Functional Evaluation of Coronary Arteries Treated With Absorb Bioresorbable Vascular Scaffold at 5-Year Follow-Up

Presenter: Luis Goncalves-Ramírez

September 17, 2022

Presentation TCT 2022

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

Presenter: Giulia Masiero

September 17, 2022

Presentation TCT 2022

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

TCT 57: Everolimus-eluting Bioresorbable Vascular Scaffolds for Coronary Atherosclerosis Restoration Therapy: Insights on Long-term Intracoronary Imaging and Physiological Results of Bioresorption

Presenter: Gabriele Pesarini

September 17, 2022

Presentation TCT 2022

TCT 56: Long-term outcomes after bioresorbable vascular scaffold implantation in patients with de-novo coronary artery disease.

Presenter: Marta Konopko

September 17, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Features

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

Shelley Wood

March 14, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

Advertisement

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

TCT 52: Structural and Functional Evaluation of Coronary Arteries Treated With Absorb Bioresorbable Vascular Scaffold at 5-Year Follow-Up

TCT 59: Impact of prolonged dual antiplatelet therapy duration on bioresorbable scaffolds outcomes: five-year data from a prospective registry.

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

TCT 57: Everolimus-eluting Bioresorbable Vascular Scaffolds for Coronary Atherosclerosis Restoration Therapy: Insights on Long-term Intracoronary Imaging and Physiological Results of Bioresorption

TCT 56: Long-term outcomes after bioresorbable vascular scaffold implantation in patients with de-novo coronary artery disease.

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content